2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies

Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home.

Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis  (https://onlinelibrary.wiley.com/doi/10.1111/dme.14585), from the team headed by Professor Golledge at the independent Queensland Research Centre for Peripheral Vascular Disease (QRC-PVD), James Cook University, Queensland, Australia, conducted a detailed meta-analysis of six recent RCTs involving 530 participants and concluded that “TOT significantly increased the likelihood of ulcer healing compared to controlswith the three trials judged to provide a low risk of bias producing a “Risk Ratio (RR) of (2.37; 95% CI 1.52, 3.68; I2 = 0%).”

The authors went further in assessing the quality of all the studies analyzed, utilizing a modified version of the foremost Cochrane Collaboration’s tool, with our TWO2 study published in Diabetes Care in 2020, entitled A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study (https://doi.org/10.2337/dc19-0476), being highlighted by a perfect 100% score.

Dr. Mike Griffiths commented: “It is refreshing to see a leading independent systematic review and meta-analysis not only affirming the now clearly proven complete healing efficacy of topical oxygen therapy, but also emphasizing the importance of the quality of such evidence, especially that supporting our unique TWO2 approach. The TWO2 study investigators purposely developed their protocol to address deficiencies and commonly seen areas for bias in most DFU studies. This included meeting all the points detailed in the 21-item checklist proposed by Professor Jeffcoate et al., in their paper entitled: Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcer, published in Diabetes Care in 2018 (https://doi.org/10.2337/dc17-1836). As the saying goes, Quality Matters!”

 

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.